BiotechTube
LamKap Bio

LamKap Bio

Basel, Switzerland· Est.
lamkapbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

LamKap Bio is a private, preclinical-stage biotech developing a pipeline of bispecific antibodies targeting solid tumors. Its core technology is the κλ-body platform, which enables the creation of fully human, multispecific antibodies designed to be 'truly natural' to potentially improve safety and efficacy. The company's most advanced program, NILK-2301 (CEA x CD3), has entered Phase 1 clinical trials, positioning it as an emerging player in the competitive T-cell engager and macrophage-redirection space for oncology.

Oncology

Technology Platform

Proprietary κλ-body platform for creating fully human, bispecific/multispecific antibodies designed to be 'truly natural' by utilizing both kappa and lambda light chains. Allows for Fc engineering to either ablate effector function (for T-cell engagers) or maintain it (for macrophage redirection).

Opportunities

The company's lead asset, NILK-2301, has entered Phase 1 trials, providing a near-term catalyst for value creation.
Its selective CD47 blocker, NILK-2401, addresses a major safety concern in the field and could differentiate it in a competitive landscape.
The platform's ability to generate both T-cell engagers and costimulatory molecules creates opportunities for internal combination therapies and partnerships.

Risk Factors

The company faces high clinical development risk with its novel bispecific antibodies, particularly regarding efficacy and safety in solid tumors.
It operates in intensely competitive therapeutic areas (CEA, CD47, GPC3) against larger, better-funded entities.
As a private, pre-revenue company, it is dependent on raising capital to fund operations and advance its pipeline.

Competitive Landscape

LamKap Bio competes in the crowded bispecific antibody oncology space. For CEA-targeting, it faces competition from Immunomedics (Trodelvy, though an ADC) and other biotechs. In CD47 inhibition, it competes with companies like Gilead (magrolimab), ALX Oncology, and others, where its selective approach is a key differentiator. Its GPC3 programs enter a field with several clinical-stage candidates, including CAR-Ts and bispecifics from other developers.

More companies in Biologics / Biosimilars →More companies in Switzerland →